How do cystic fibrosis clinic nurses explain CFTR modulator therapy to Spanish-speaking patients who believe the medication has cured their CF?

The most dangerous misunderstanding about CFTR modulator therapy in the CF clinic is the belief that dramatic clinical improvement means the underlying disease has been cured and the medication can be stopped. This misunderstanding is understandable: patients who have spent years with chronic cough, frequent hospitalizations, weight loss, and progressive breathlessness experience what feels like a return to health when a CFTR modulator like elexacaftor-tezacaftor-ivacaftor (Trikafta) becomes effective. FEV1 can improve by 10 to 15 percentage points or more, exacerbation rates drop dramatically, weight normalizes, and quality of life improves in ways the patient may not have experienced in years. The CF clinic nurse explaining why this improvement does not mean the medication can be stopped needs to explain the distinction between correcting a protein and curing a gene. Cystic fibrosis is caused by mutations in the CFTR gene, which provides the instructions for making the CFTR chloride channel protein. In the most common CF-causing mutation (F508del), the protein folds incorrectly and is destroyed by the cell's quality-control system before it reaches the cell surface where it belongs. CFTR modulators like elexacaftor-tezacaftor-ivacaftor are molecular correctors and potentiators that bind to the misfolded CFTR protein and help it fold correctly, escort it to the cell surface, and improve its function once it gets there. The medication does not change the gene. Every day that the patient takes Trikafta, the medication is doing the molecular correction work in real time. Every day the patient stops, the misfolded protein is no longer corrected, the cell destroys it, and the channel is absent from the cell surface. The thick, sticky mucus that accumulates in the CF lung in the absence of functional CFTR does not take long to return. Patients who have stopped CFTR modulator therapy for any reason — including the belief that they were cured — have universally experienced return of symptoms. “El medicamento no cura la fibrosis quística — corrige el problema de la proteína mientras usted lo está tomando. El gen no cambia. Cada día que toma el medicamento, el medicamento está haciendo el trabajo de corregir la proteína ese día. Cuando lo deja de tomar, la proteína ya no se corrige, la célula la destruye, y el canal que necesita el pulmón para mover el moco deja de estar. La mejora que usted y su amigo sintieron fue el medicamento funcionando, no la enfermedad desapareciendo. Esa mejoría dura mientras el medicamento dura.” (The medication does not cure cystic fibrosis — it corrects the protein problem while you are taking it. The gene does not change. Every day you take the medication, the medication is doing the work of correcting the protein that day. When you stop taking it, the protein is no longer corrected, the cell destroys it, and the channel the lung needs to move mucus stops being there. The improvement you and your friend felt was the medication working, not the disease disappearing. That improvement lasts as long as the medication lasts.)

How do cystic fibrosis clinic nurses explain to Spanish-speaking patients why pulmonary exacerbations cause permanent lung function loss?

One of the most difficult conversations in CF clinic nursing is with the patient whose FEV1 has not recovered after a pulmonary exacerbation despite completing a full course of IV antibiotics. The patient's experience is that she took two weeks of intravenous antibiotics as directed, felt somewhat better, and then discovered at her next spirometry appointment that her lung function had not returned to where it was before the exacerbation. If this happens once, it is surprising. If it happens twice, the patient may reasonably conclude that the IV antibiotics are not working and decline a third course. The CF clinic nurse needs to explain the distinction between what IV antibiotics do and what a pulmonary exacerbation does. A pulmonary exacerbation is not simply an infection that, once treated, leaves the lung in its prior state. A CF pulmonary exacerbation involves a cascade of inflammation — triggered partly by increased bacterial burden but driven significantly by the immune response to that burden — that damages the airway walls, causes mucus plugging in small airways, and contributes to progressive bronchiectasis (irreversible widening and scarring of the bronchial walls). The IV antibiotics reduce the bacterial load that is driving the inflammatory cascade, which is why they reduce symptoms, reduce sputum volume, and improve quality of life. They do not rebuild the airway wall tissue that the inflammation damaged. Once bronchiectasis has developed in an area of the lung, it is permanent. The FEV1 that the patient had before the exacerbation reflected the structural state of the lung at that point; the FEV1 after the exacerbation reflects the structural state after the exacerbation's inflammatory damage. The goal of IV antibiotics is not to restore the pre-exacerbation FEV1 — it is to prevent the exacerbation from causing even greater permanent damage, to prevent the patient from developing respiratory failure during the acute phase, and to reduce the frequency of future exacerbations by suppressing the bacterial burden. Without treatment, exacerbations cause more permanent damage than with treatment. The decision to decline IV antibiotics does not preserve the patient's current lung function; it allows the exacerbation to run a longer and more destructive course. “Los antibióticos intravenosos no pueden recuperar la función pulmonar que la exacerbación ya destruyó — esa parte es permanente. Lo que pueden hacer es detener que la exacerbación siga destruyendo más tejido, evitar que llegue a una crisis respiratoria, y reducir el riesgo de que la próxima exacerbación pase antes de tiempo. Sin tratamiento, el daño de esta exacerbación será más grande, no igual.” (The IV antibiotics cannot recover the lung function the exacerbation already destroyed — that part is permanent. What they can do is stop the exacerbation from continuing to destroy more tissue, prevent it from reaching a respiratory crisis, and reduce the risk of the next exacerbation coming before its time. Without treatment, the damage from this exacerbation will be larger, not the same.)

How do cystic fibrosis clinic nurses explain CF-related diabetes to Spanish-speaking patients who are managing it with caloric restriction?

CF-related diabetes (CFRD) is the most common comorbidity in adults with cystic fibrosis, occurring in approximately 20 to 25 percent of CF adults, and it is a biologically distinct form of diabetes that behaves differently from both type 1 and type 2 diabetes in ways that have direct consequences for patient education. CFRD develops when progressive fibrosis of the exocrine pancreas damages the insulin-producing beta cells — the same pancreatic fibrosis that causes CF-related pancreatic insufficiency — producing a state of relative insulin deficiency. Unlike type 2 diabetes, CFRD involves little or no insulin resistance; the problem is insufficient insulin secretion, not cellular resistance to insulin's signal. Unlike type 1 diabetes, the loss of beta cells is gradual and often produces a pattern of delayed insulin secretion rather than complete absence, which is why fasting blood sugars in CFRD are often normal while postprandial blood sugars are elevated. When a Spanish-speaking CF patient with CFRD begins managing her blood sugars by restricting carbohydrates and overall calories, her postprandial readings may improve — she is consuming less glucose, so the peak is lower. Her HbA1c may improve. She may believe she has found an effective management strategy. The CF clinic nurse needs to explain why this belief, while understandable, is actively harmful in CF. CF patients require 120 to 150 percent of the caloric intake of a healthy adult of the same age and size, not because CF increases appetite but because the disease imposes a dramatically elevated energy cost: the work of breathing against obstructed and stiffened airways consumes calories continuously, chronic airway infection drives an inflammatory metabolic demand, and malabsorption from pancreatic insufficiency reduces the fraction of consumed calories that actually reach the body. When a CF patient loses weight, the first organ systems to suffer are those that depend on nutritional substrate: the respiratory muscles (diaphragm, intercostals, accessory muscles) that drive the cough mechanism; the immune cells that patrol the airway; and the mucociliary system that clears bacteria. A nine-pound weight loss in a CF patient over four months represents a measurable reduction in respiratory muscle strength, measurable reduction in peak cough flow, and measurable increase in mucus retention. The connection between that weight loss and the seven-point FEV1 decline is not coincidental. The treatment for CFRD is insulin — typically rapid-acting insulin at meals calibrated to the high-calorie CF diet — not reduction in calories. The goal is to provide enough insulin to handle the carbohydrate load of a diet that CF lungs require, not to reduce the diet to avoid needing insulin. “La diabetes relacionada con la fibrosis quística no se trata reduciendo calorías — se trata con insulina para que pueda comer lo que su pulmón necesita. En la fibrosis quística, el cuerpo quema el doble de calorías que una persona sana del mismo tamaño porque respirar con pulmones obstruidos cuesta energía constantemente, la infección crónica cuesta energía, y la mala absorción del páncreas significa que parte de lo que come no llega. Cuando usted pierde peso, el diafragma y los músculos de la tos pierden fuerza. Esa pérdida de fuerza significa que el moco se mueve peor, las bacterias se acumulan más, y el pulmón tiene más exacerbaciones. La insulina es el tratamiento — no para reemplazar las calorías, sino para procesarlas.” (CF-related diabetes is not treated by reducing calories — it is treated with insulin so you can eat what your lung needs. In cystic fibrosis, the body burns twice the calories of a healthy person the same size because breathing with obstructed lungs costs energy constantly, chronic infection costs energy, and malabsorption from the pancreas means some of what you eat does not arrive. When you lose weight, the diaphragm and the cough muscles lose strength. That loss of strength means mucus moves worse, bacteria accumulate more, and the lung has more exacerbations. Insulin is the treatment — not to replace the calories, but to process them.)

How do cystic fibrosis clinic nurses help Spanish-speaking adolescents with CF understand why their peers' experiences with the disease may differ significantly from their own?

Adolescence in CF care presents a specific communication challenge: teenagers with CF often know other teenagers with CF, and the variation in disease presentation, genotype, and treatment response between patients can create misinformation that travels through peer networks with the authority of lived experience. A patient whose friend experienced dramatic improvement on Trikafta and mistakenly concluded that CF was cured is acting on information that was real for his friend — the improvement was real; only the interpretation of what the improvement meant was incorrect. Similarly, a patient whose friend has a different CF genotype and takes different medications, or who has a milder phenotype and fewer exacerbations, may calibrate his own management decisions based on a comparison that does not apply to his biology. The CF clinic nurse working with Spanish-speaking adolescent patients needs to address peer information without dismissing the peer's authority — an approach that tells the patient “your friend is wrong” will not be credible to an adolescent who trusts his friend's direct experience. The more effective approach is to validate the peer's experience, explain why the interpretation was incorrect, and then personalize the explanation to the patient's specific lab values, spirometry trend, and genotype. The patient who understands his own F508del/F508del genotype, his own FEV1 trajectory, and his own HbF data is in a position to evaluate his friend's information against his own situation rather than simply accepting or rejecting it. “Lo que le pasó a su amigo fue real — la mejora fue real, la sensación de estar bien fue real. Lo que no era correcto era la conclusión: que si te sientes bien, el medicamento ya no es necesario. El medicamento es la razón por la que se siente bien. Cuando lo deja, la razón desaparece. Y lo que vemos en sus espirometrías de las últimas seis semanas nos dice que el proceso ya está ocurriendo en usted.” (What happened to your friend was real — the improvement was real, the feeling of being well was real. What was not correct was the conclusion: that if you feel well, the medication is no longer necessary. The medication is the reason you feel well. When you stop it, the reason disappears. And what we see in your spirometries over the last six weeks tells us that the process is already happening in you.)

What are the most important Spanish phrases for cystic fibrosis clinic nurses?

Cystic fibrosis clinic nursing involves three recurring communication failures with Spanish-speaking patients. The first is the patient who has stopped or is considering stopping a CFTR modulator because dramatic improvement has been misread as cure — a misreading that peer networks in the CF community can reinforce with the weight of lived experience. The second is the patient who has experienced FEV1 non-recovery after pulmonary exacerbations and concludes that IV antibiotics have stopped working — a logical conclusion from incomplete information that leads to refusal of a treatment that, while unable to restore lost function, prevents further irreversible loss. The third is the patient with CF-related diabetes who is managing blood sugars by the most intuitive available mechanism — caloric restriction — without understanding that in CF, nutritional depletion is itself a mechanism of lung function decline. For CFTR modulator adherence: “el medicamento corrige la proteína cada día que usted lo toma; cuando lo deja, la corrección se detiene; la mejoría que sintió era el medicamento trabajando, no la enfermedad desapareciendo.” For pulmonary exacerbation and irreversible FEV1 decline: “los antibióticos intravenosos no pueden recuperar la función pulmonar que la exacerbación ya destruyó — eso es permanente; lo que pueden hacer es detener que esta exacerbación siga destruyendo más, y sin tratamiento el daño será mayor.” For CF-related diabetes and caloric restriction: “en la fibrosis quística, perder peso debilita los músculos de la tos y del pulmón; la diabetes relacionada con fibrosis quística se trata con insulina para procesar las calorías que su pulmón necesita, no reduciendo las calorías para no necesitar la insulina.” For explaining why airway clearance matters even when feeling better: “el moco en los pulmones de la fibrosis quística se acumula aunque no se sienta mal; la terapia de depuración de vías aéreas mueve ese moco antes de que las bacterias que viven en él tengan tiempo de multiplicarse y empezar una exacerbación.” (For CFTR modulator adherence: “the medication corrects the protein every day you take it; when you stop, the correction stops; the improvement you felt was the medication working, not the disease disappearing.” For pulmonary exacerbation and irreversible FEV1 decline: “IV antibiotics cannot recover the lung function the exacerbation already destroyed — that is permanent; what they can do is stop this exacerbation from continuing to destroy more, and without treatment the damage will be larger.” For CF-related diabetes and caloric restriction: “in cystic fibrosis, losing weight weakens the cough and lung muscles; CF-related diabetes is treated with insulin to process the calories your lung needs, not by reducing the calories to avoid needing insulin.” For explaining why airway clearance matters even when feeling better: “the mucus in the cystic fibrosis lung accumulates even when you do not feel bad; airway clearance therapy moves that mucus before the bacteria that live in it have time to multiply and start an exacerbation.”)

July 23, 2026 · Clinical Spanish · Cystic Fibrosis · Pulmonology Nursing · Chronic Disease Management

Spanish for cystic fibrosis clinic nurses — the adolescent who stopped Trikafta because a friend told him it was a cure, the patient whose FEV1 fell from 65% to 48% and who refuses IV antibiotics because she thinks they stopped working, and the patient with CF-related diabetes who has been restricting calories for four months and is inadvertently accelerating her lung disease

Adrián Molina is 17. He is a high school senior from Riverside, California, with cystic fibrosis — genotype F508del/F508del, the most common CF-causing mutation in the United States. He was diagnosed at ten days old through newborn screening. For most of his childhood, CF meant daily airway clearance, pancreatic enzyme replacement with every meal, frequent pulmonary function tests, and an average of two pulmonary exacerbations per year requiring oral or IV antibiotics.

Fourteen months ago, he started elexacaftor-tezacaftor-ivacaftor — the triple-combination CFTR modulator marketed as Trikafta. His FEV1 at the time of initiation was 72% predicted. At his three-month follow-up, it was 84%. At six months, 89%. At twelve months, 91%. He had zero pulmonary exacerbations in those fourteen months. He gained nine pounds. His cough, which had been chronic and productive since early childhood, became occasional and dry. His mother told the CF clinic nurse that Adrián had started playing pickup basketball with the neighborhood kids for the first time.

Six weeks ago, Adrián stopped taking Trikafta.

He stopped because a friend from the CF clinic — a boy he has known since he was twelve, who has the same F508del/F508del genotype and who started Trikafta six months before Adrián did — pulled him aside at a social event and told him something in confidence.

— Me dijeron que ya no tengo que tomarlo. Mi doctor dijo que ya limpié la fibrosis quística. Estoy bien ahora. Me descontinuaron el medicamento el mes pasado.

They told me I no longer have to take it. My doctor said I have already cleared the cystic fibrosis. I am fine now. They discontinued the medication last month.

Adrián spent the next three days thinking about this. He felt fine. He had felt fine for months. If his friend — who had the same disease, the same mutation, and the same medication — had been told he was cured, maybe he was also cured, and maybe the daily pill that cost him a moment of planning every morning was no longer necessary. He stopped taking the Trikafta without telling anyone.

He is in the CF clinic today for a scheduled visit. His FEV1 is 74%.

— ¿Cuándo fue la última vez que tomó el medicamento?

When was the last time you took the medication?

What this post covers

This post covers three conversations that recur in cystic fibrosis clinic nursing when the patient speaks Spanish. The first is Adrián’s — the patient who stopped a CFTR modulator because a trusted peer, speaking from genuine (if misunderstood) experience, communicated that the medication was no longer necessary. The second is Gloria Reyes, 52, a school cafeteria worker from San Antonio whose FEV1 fell from 65% to 56% after her first pulmonary exacerbation eighteen months ago and from 56% to 48% after her second exacerbation eight months ago, neither time returning to baseline despite completing full courses of IV antibiotics. She is now developing signs of a third exacerbation and is refusing to begin another IV course because she believes, with reasonable logic, that the antibiotics stopped working. The third is Carmen Vidal, 34, a medical billing specialist from Miami with CF and CF-related diabetes diagnosed eight months ago. Carmen has been restricting carbohydrates and total calories for the past four months in order to control her blood sugars. Her postprandial readings have improved. Her HbA1c has improved. She has lost nine pounds. And her FEV1 has dropped from 71% to 64%, with an exacerbation frequency that is increasing for the first time in three years.

In each case the patient is acting on a coherent understanding of incomplete information. In each case the CF clinic nurse who explains the mechanism — what CFTR modulators actually do and do not do, what pulmonary exacerbations actually destroy, what caloric restriction actually costs in the CF lung — is the person who prevents the logical conclusion from becoming the catastrophic one.

Scenario one: Adrián and the cure that was not a cure

The CF clinic nurse, Mónica Espinoza, has worked in the CF clinic at the children’s hospital for nine years. She has navigated the transition of the Trikafta era with patients who were too young to remember what their lungs felt like before the medication and with parents who watched their children return from a life measured in hospitalizations to a life that looked, from the outside, like the life of a healthy teenager. She has also learned that this transformation carries a specific risk: the better patients feel, the harder it becomes to explain why they must take a daily medication indefinitely.

She looks at the spirometry result from today’s visit and then at Adrián’s chart. Six weeks ago: 91%. Today: 74%. A seventeen-percentage-point drop in six weeks, tracking exactly toward his pre-treatment baseline of 72%.

Mónica: — Adrián, veo en sus pruebas de hoy que su función pulmonar bajó bastante comparado con hace tres meses. De 91% a 74%. Antes de que hablemos de los resultados, quiero entender si algo ha cambiado en lo que estaba haciendo en casa.

Adrián, I see in today’s tests that your lung function has dropped considerably compared to three months ago. From 91% to 74%. Before we talk about the results, I want to understand if something has changed in what you were doing at home.

Adrián tells her. He tells her about his friend, about what his friend said, about the three days of thinking, about stopping the Trikafta.

Mónica does not correct him immediately. She knows the correction has to land somewhere specific to be credible, and she knows that telling a teenager that his friend was wrong is the least effective route to that landing place.

Mónica: — Primero quiero entender lo que le pasó a su amigo, porque lo que le dijo claramente tuvo sentido para usted. ¿Su amigo ha hablado con usted desde que le dijo eso?

I want to first understand what happened with your friend, because what he told you clearly made sense to you. Has your friend spoken with you since he told you that?

Adrián: — No desde entonces. Creo que sus padres le dijeron que no hablara sobre el medicamento con otros pacientes.

Not since then. I think his parents told him not to talk about the medication with other patients.

Mónica: — Eso me ayuda a entender lo que pudo haber pasado. ¿Le dió permiso de compartir lo que voy a decirle?

That helps me understand what may have happened. Does he have your permission to share what I am going to tell you?

What CFTR modulators do and what they do not do

Mónica: — La fibrosis quística es causada por una mutación en el gen que le da instrucciones a su cuerpo para hacer una proteína que se llama CFTR. La función de esa proteína es actuar como un canal en las células que recubren sus pulmones, su páncreas, sus intestinos — un canal que permite que el cloruro y el agua se muevan a través de la célula. Cuando el canal funciona correctamente, el moco en los pulmones es delgado y se mueve. Cuando el canal no funciona, el moco es espeso y se queda.

Cystic fibrosis is caused by a mutation in the gene that gives your body instructions to make a protein called CFTR. The function of that protein is to act as a channel in the cells lining your lungs, your pancreas, your intestines — a channel that allows chloride and water to move across the cell. When the channel works correctly, the mucus in the lungs is thin and moves. When the channel does not work, the mucus is thick and stays.

Adrián: — Eso lo sé.

I know that.

Mónica: — Perfecto. Lo que hace la Trikafta es específico: le ayuda a la proteína CFTR que su cuerpo ya está produciendo a doblarse de la manera correcta y a llegar a la superficie de la célula donde pertenece. Su mutación — la F508del que tiene en los dos cromosomas — hace que la proteína se doble mal y que la célula la destruya antes de que llegue a donde tiene que ir. El medicamento actúa como una especie de andamio molecular que le da soporte a la proteína mientras se está formando para que no se doble mal. El resultado: la proteína llega a la superficie, el canal funciona, el moco se adelgaza, el pulmón respira mejor.

Perfect. What Trikafta does is specific: it helps the CFTR protein your body is already producing to fold correctly and reach the cell surface where it belongs. Your mutation — the F508del you have on both chromosomes — causes the protein to fold incorrectly and the cell to destroy it before it reaches where it needs to go. The medication acts like a kind of molecular scaffold that gives the protein support while it is forming so it does not fold incorrectly. The result: the protein reaches the surface, the channel works, the mucus thins, the lung breathes better.

Adrián: — Eso también lo sé. Por eso me mejoré.

I know that too. That is why I improved.

Mónica: — Exactamente. Ahora aquí está la parte que marca la diferencia: el medicamento no cambia el gen. El gen sigue siendo F508del. Lo que cambia mientras usted toma el medicamento es que el medicamento está haciendo el trabajo de corrección en tiempo real, cada día. Cada mañana que toma la Trikafta, el medicamento está presente en las células de su pulmón haciendo ese andamio molecular. Cada mañana que no la toma, ese andamio no existe. La proteína se sigue produciendo — el gen sigue ahí — pero se sigue doblando mal, la célula la sigue destruyendo, y el canal sigue sin llegar a la superficie.

Exactly. Now here is the part that makes the difference: the medication does not change the gene. The gene is still F508del. What changes while you take the medication is that the medication is doing the correction work in real time, every day. Every morning that you take the Trikafta, the medication is present in the cells of your lung building that molecular scaffold. Every morning that you do not take it, that scaffold does not exist. The protein is still being produced — the gene is still there — but it keeps folding incorrectly, the cell keeps destroying it, and the channel keeps not reaching the surface.

Adrián: — Entonces no me curé. Estaba funcionando.

So I was not cured. It was working.

Mónica: — Estaba funcionando exactamente como debería. El 91% que llegó a los doce meses — ese número no existía sin el medicamento. Y la caída que vemos hoy — de 91% a 74% en seis semanas — nos está diciendo que el pulmón ya está respondiendo a la ausencia del medicamento. Estamos viendo hacia dónde va si no lo reiniciamos: de regreso a los 72% donde empezó.

It was working exactly as it should. The 91% you reached at twelve months — that number did not exist without the medication. And the drop we are seeing today — from 91% to 74% in six weeks — is telling us that the lung is already responding to the absence of the medication. We are seeing where it is going if we do not restart it: back to the 72% where it started.

What probably happened with Adrián’s friend

Mónica: — ¿Puedo hablarle sobre lo que probablemente le pasó a su amigo? No sé los detalles de su caso porque no es mi paciente, pero puedo decirle lo que hemos visto en algunos pacientes durante estos años.

May I tell you about what probably happened with your friend? I do not know the details of his case because he is not my patient, but I can tell you what we have seen in some patients during these years.

Adrián: — Sí.

Yes.

Mónica: — Lo que su amigo le contó — que su doctor le dijo que ya limpió la fibrosis quística y que descontinuó el medicamento — no suena como algo que un médico de fibrosis quística diría, porque no es algo que sea clínicamente cierto. Lo que puede haber pasado es que su amigo escuchó algo diferente de lo que le dijeron, o que alguien le explicó su mejoría de una manera que él interpretó como cura. Lo que es seguro es que si realmente dejó de tomar la Trikafta, también está viendo lo que usted está viendo ahora — una caída en su función pulmonar. Y si sus padres le dijeron que no hablara sobre el medicamento con otros pacientes, eso es probablemente porque se dieron cuenta de lo que pasó.

What your friend told you — that his doctor told him he had cleared the cystic fibrosis and discontinued the medication — does not sound like something a CF physician would say, because it is not something that is clinically true. What may have happened is that your friend heard something different from what was said to him, or that someone explained his improvement in a way he interpreted as a cure. What is certain is that if he really stopped taking Trikafta, he is also seeing what you are seeing now — a drop in his lung function. And if his parents told him not to talk about the medication with other patients, that is probably because they realized what happened.

Adrián is quiet for a moment.

Adrián: — ¿Lo voy a recuperar? ¿Los 91%?

Am I going to get it back? The 91%?

Mónica: — En la mayoría de los pacientes que reinician después de una pausa de pocas semanas, la función pulmonar vuelve al nivel donde estaba. Seis semanas no es un período largo de tiempo. Vamos a reiniciarlo hoy, y vamos a ver los números en tres meses. Lo que no quiero es que esta pausa se extienda, porque cuanto más tiempo pasa sin el medicamento, más oportunidad tiene el pulmón de desarrollar inflamación y daño que son más difíciles de revertir.

In most patients who restart after a pause of a few weeks, lung function returns to the level it was at. Six weeks is not a long period of time. We are going to restart it today, and we are going to see the numbers in three months. What I do not want is for this pause to extend, because the longer time passes without the medication, the more opportunity the lung has to develop inflammation and damage that are harder to reverse.

Adrián: — ¿Y si le digo a mi amigo lo que me dijo usted?

And if I tell my friend what you told me?

Mónica: — Creo que sería útil. Cuéntele exactamente lo que le expliqué: que el medicamento corrige la proteína mientras usted lo está tomando, que el gen no cambia, y que la mejoría dura mientras el medicamento dura. Eso no es una opinión — eso es lo que vemos en las espirometrías de cada paciente que ha hecho pausa, incluida la suya de hoy.

I think it would be useful. Tell him exactly what I explained to you: that the medication corrects the protein while you are taking it, that the gene does not change, and that the improvement lasts as long as the medication lasts. That is not an opinion — that is what we see in the spirometries of every patient who has paused, including yours today.

Scenario two: Gloria and the antibiotics she thinks stopped working

Gloria Reyes is 52. She has had cystic fibrosis for her entire life, but she was not diagnosed until she was seven — an era before universal newborn screening, when a child from a Spanish-speaking family in San Antonio with chronic respiratory infections could accumulate years of lung damage before anyone connected the dots. Her genotype is F508del/3849+10kbC→T, a compound heterozygous genotype in which the second mutation is a milder splice variant that produces some residual CFTR function. She does not qualify for Trikafta’s approved indication in the current prescribing label. She has managed her CF with airway clearance, inhaled antibiotics, and intermittent IV antibiotic courses for exacerbations since she was a teenager.

Eighteen months ago, she had a pulmonary exacerbation that required a fourteen-day course of IV tobramycin and ceftazidime. At the time of admission her FEV1 was 65%. At the end of the course she was discharged with an FEV1 of 60%. At her one-month follow-up, it was 58%. At three months, 57%. Her FEV1 did not return to 65%.

Eight months ago, she had a second exacerbation. Her FEV1 at the time of the second admission was 56%. She completed another fourteen-day course. At discharge: 51%. At one month: 49%. At three months: 48%. Her FEV1 did not return to 56%.

She is in the CF clinic today because the CF clinic nurse flagged her sputum culture from last week — increased Pseudomonas aeruginosa density, new mucoid morphotype — and her reported symptoms are consistent with an early pulmonary exacerbation: increased cough frequency, change in sputum color from yellow to green, ten days of fatigue that is not explained by sleep, and a three-pound weight loss. Today’s FEV1 is 45%.

The clinic nurse, Elena Torres, tells Gloria that she needs to be admitted for IV antibiotics.

— No. Ya los tomé dos veces y mi pulmón nunca se recuperó. No quiero tomar dos semanas de medicamento por nada.

No. I already took them twice and my lung never recovered. I do not want to take two weeks of medication for nothing.

What a pulmonary exacerbation actually destroys

Elena Torres has been working in adult CF for fourteen years. She knows that the conversation she needs to have with Gloria is not about the antibiotics. It is about what happened to the 65% and why the antibiotics were never going to bring it back.

Elena: — Gloria, escucho lo que me está diciendo, y tiene razón en algo importante: su pulmón no volvió al 65% después de la primera hospitalización, ni al 56% después de la segunda. Eso es real. Antes de hablar sobre lo que queremos hacer ahora, quiero explicarle por qué pasó eso, porque creo que si entiende lo que le pasa al pulmón durante una exacerbación, lo que vino después va a tener más sentido.

Gloria, I hear what you are telling me, and you are right about something important: your lung did not return to 65% after the first hospitalization, or to 56% after the second. That is real. Before we talk about what we want to do now, I want to explain to you why that happened, because I believe that if you understand what happens to the lung during an exacerbation, what came after will make more sense.

Gloria: — ¿Por qué? Si los antibióticos no funcionaron, saber por qué no cambia nada.

Why? If the antibiotics did not work, knowing why does not change anything.

Elena: — Porque los antibióticos sí funcionaron — pero funcionaron para algo diferente de lo que usted pensaba que estaban haciendo. Y la diferencia importa para entender por qué la situación de ahora es diferente a no hacer nada.

Because the antibiotics did work — but they worked for something different from what you thought they were doing. And the difference matters for understanding why the situation now is different from doing nothing.

The structural damage of CF exacerbations

Elena: — En la fibrosis quística, las bacterias que colonizan el pulmón — principalmente la Pseudomonas aeruginosa en su caso — producen inflamación. No es solo la bacteria dañando el tejido directamente: es que la respuesta del sistema inmunológico a la bacteria, los glóbulos blancos que van a atacar la infección, liberan enzimas y substancias que dañan el tejido de los bronquios mientras están peleando. Durante una exacerbación, esa inflamación se intensifica. El daño al tejido bronquial se accelera. Los bronquios que ya estaban dilatados y engrosados por años de inflamación crónica sufren más daño. Ese daño — la bronquiectasia, el engrosamiento de la pared bronquial, la obstrucción de pequeñas vías aéreas — es permanente. No se repara.

In cystic fibrosis, the bacteria that colonize the lung — mainly Pseudomonas aeruginosa in your case — produce inflammation. It is not just the bacteria directly damaging the tissue: it is that the immune system’s response to the bacteria, the white blood cells that go to attack the infection, release enzymes and substances that damage the bronchial tissue while they are fighting. During an exacerbation, that inflammation intensifies. The damage to the bronchial tissue accelerates. The bronchi that were already dilated and thickened from years of chronic inflammation suffer more damage. That damage — bronchiectasis, bronchial wall thickening, small airway obstruction — is permanent. It does not repair itself.

Gloria: — Entonces cuando terminé los antibióticos y mi función pulmonar no volvió al 65%...

So when I finished the antibiotics and my lung function did not return to 65%...

Elena: — El daño que la exacerbación hizo al tejido bronquial era real y permanente. El 65% era el reflejo del estado de su pulmón antes de la exacerbación — con el daño que tenía en ese momento. El 57% que quedó después refleja el estado después del daño adicional que la exacerbación causó. Los antibióticos suprimieron la infección al nivel donde el sistema inmunológico pudo controlar la inflamación, lo cual es por qué usted se sintió mejor y por qué pudo salir del hospital. Pero no pueden reconstruir el tejido que ya fue destruido. Nadie puede hacer eso.

The damage the exacerbation did to the bronchial tissue was real and permanent. The 65% was the reflection of the state of your lung before the exacerbation — with the damage it had at that point. The 57% that remained afterward reflects the state after the additional damage the exacerbation caused. The antibiotics suppressed the infection to the level where the immune system could control the inflammation, which is why you felt better and why you could leave the hospital. But they cannot rebuild tissue that has already been destroyed. Nobody can do that.

Gloria: — Entonces ¿para qué sirve hacer lo mismo de nuevo si el resultado va a ser el mismo?

Then what is the point of doing the same thing again if the result is going to be the same?

What happens without treatment and why treatment still matters

Elena: — Porque el resultado sin tratamiento no es el mismo. Es peor. Gloria, lo que estamos viendo ahora — el cultivo de la semana pasada, los síntomas que me describió, el 45% de hoy que bajó desde el 48% del mes pasado — eso es una exacerbación que está empezando. Si la tratamos ahora, con dos semanas de antibióticos intravenosos dirigidos a la bacteria específica que tenemos en el cultivo, lo que podemos esperar es que la infección se suprima antes de que cause el máximo de daño. Lo que no podemos prometer es que el pulmón regrese al 48%. Eso ya no lo podemos prometer porque hay daño permanente de las dos exacerbaciones anteriores. Lo que sí podemos prometer es que sin tratamiento, la exacerbación va a durar más, va a causar más inflamación, va a dañar más tejido bronquial, y el punto donde se estabilice va a ser más bajo que si la tratamos ahora.

Because the result without treatment is not the same. It is worse. Gloria, what we are seeing now — last week’s culture, the symptoms you described to me, the 45% today that fell from 48% last month — that is an exacerbation that is beginning. If we treat it now, with two weeks of IV antibiotics targeted to the specific bacteria in the culture, what we can expect is that the infection is suppressed before it causes the maximum damage. What we cannot promise is that the lung will return to 48%. We can no longer promise that because there is permanent damage from the two previous exacerbations. What we can promise is that without treatment, the exacerbation will last longer, will cause more inflammation, will damage more bronchial tissue, and the point where it stabilizes will be lower than if we treat it now.

Gloria: — ¿Cuánto más bajo?

How much lower?

Elena: — No podemos saberlo con exactitud. Pero lo que sí sabemos, de los estudios que siguen a pacientes con fibrosis quística a lo largo del tiempo, es que las exacerbaciones que se tratan con antibióticos intravenosos tienen menos pérdida permanente de función pulmonar que las exacerbaciones que no se tratan o que se tratan solo con antibióticos orales. Incluso cuando la recuperación no es completa — como en sus dos hospitalizaciones anteriores — el daño es menor con tratamiento que sin él.

We cannot know exactly. But what we do know, from studies that follow CF patients over time, is that exacerbations treated with IV antibiotics have less permanent lung function loss than exacerbations not treated or treated only with oral antibiotics. Even when recovery is not complete — as in your two previous hospitalizations — the damage is less with treatment than without.

Gloria is quiet for a long moment. She looks at the spirometry tracing in her chart.

Gloria: — ¿45% es el número que me debo quedar?

Is 45% the number I have to stay at?

Elena: — No si tratamos esto ahora. El objetivo no es recuperar el 65% — ese objetivo ya no está disponible. El objetivo es que dentro de tres meses estemos mirando un número que está lo más cerca posible del 48%, no al 38% o al 35%. Los antibióticos no pueden deshacer el daño que ya pasó. Pero sí pueden ser la diferencia entre el pulmón que tiene hoy y el pulmón que tendría dentro de un mes si dejamos que esto siga sin tratamiento.

Not if we treat this now. The goal is not to recover the 65% — that goal is no longer available. The goal is that in three months we are looking at a number that is as close as possible to 48%, not at 38% or 35%. The antibiotics cannot undo the damage that has already happened. But they can be the difference between the lung you have today and the lung you would have in a month if we let this continue without treatment.

Gloria: — ¿Me están diciendo que el objetivo ahora es frenar la caída, no recuperarme?

Are you telling me that the goal now is to slow the fall, not to recover?

Elena: — Eso es una manera honesta de decirlo. Frenar la caída todo lo que sea posible, en cada exacerbación, es lo que mantiene la función pulmonar que le queda por más tiempo. Y la función pulmonar que le queda es lo que determina cómo va a estar en cinco años.

That is an honest way to say it. Slowing the fall as much as possible, in each exacerbation, is what preserves the lung function you have left for longer. And the lung function you have left is what determines how you will be in five years.

Gloria: — Está bien. Llamen a mi hija para que sepa que me voy a quedar.

All right. Call my daughter so she knows I am staying.

Scenario three: Carmen and the calories she stopped eating

Carmen Vidal is 34. She has had cystic fibrosis since birth, diagnosed at six weeks old, and she has managed it with the discipline of someone who knows that her daily choices have measurable consequences. She does her airway clearance twice a day, every day. She takes her pancreatic enzyme replacement with every meal. She does not smoke. She has not been hospitalized for a pulmonary exacerbation in three years, and her FEV1 had been stable at 71% for the last eighteen months.

Eight months ago, her CF clinic visit included a glucose tolerance test — standard screening for CF-related diabetes — and her two-hour postprandial glucose came back at 218 mg/dL. She was diagnosed with CF-related diabetes. Her fasting glucose was 97 mg/dL — normal. Her HbA1c was 6.4% — in the prediabetic range, not yet clearly diabetic.

The CF clinic started her on rapid-acting insulin at meals. Carmen filled the prescription. She also went home and began reading about diabetes management. She read about the glycemic index. She read about low-carbohydrate diets. She read forums where people with type 2 diabetes described reversing their condition through dietary changes. Four months ago, she stopped the insulin and began a caloric restriction plan: no simple carbohydrates, no more than 1,400 calories per day, half of her previous portion sizes at each meal.

Her most recent fasting glucose: 91 mg/dL. Her postprandial glucose after a 1,400-calorie day: 134 mg/dL. Her HbA1c: 5.9%. By every blood sugar metric, she has succeeded.

She has lost nine pounds in four months. Her FEV1 today is 64%.

— No entiendo por qué el equipo está preocupado. Mis azúcares nunca han estado tan bien.

I do not understand why the team is worried. My blood sugars have never been this good.

Why CF-related diabetes is not like other diabetes

The CF clinic nurse, Rosa Jiménez, has been in adult CF for seven years. She has had the CFRD conversation before, but Carmen’s version of it has a specific complication: by every metric Carmen is tracking, she is succeeding. Her numbers are better. The challenge is that the metric she is using to measure success — blood sugar — is not the metric that matters most in CF. The metric that matters most in CF is lung function, and lung function is declining.

Rosa: — Carmen, quiero empezar reconociendo algo: lo que usted hizo funcionó para bajar los azúcares. Los números que me está mostrando son buenos. No estoy diciendo que lo que hizo no tuvo efecto — sí lo tuvo. Pero en la fibrosis quística, la relación entre los azúcares, las calorías y el pulmón es diferente que en otros tipos de diabetes, y esa diferencia es lo que quiero explicarle, porque creo que si la entiende, lo que estamos viendo en su espirometría va a tener sentido de una manera que no lo ha tenido hasta ahora.

Carmen, I want to start by acknowledging something: what you did worked to lower your blood sugars. The numbers you are showing me are good. I am not saying that what you did had no effect — it did. But in cystic fibrosis, the relationship between blood sugar, calories, and the lung is different from other types of diabetes, and that difference is what I want to explain to you, because I believe that if you understand it, what we are seeing in your spirometry will make sense in a way it has not until now.

Carmen: — ¿La espirometría bajó porque dejé la insulina?

Did my spirometry drop because I stopped the insulin?

Rosa: — Bajó porque bajó el peso. Y el peso bajó porque usted recortó las calorías. Eso es lo que quiero explicarle, porque en cualquier otro tipo de diabetes, recortar calorías para bajar el azúcar es una estrategia que tiene sentido. En la fibrosis quística, no la tiene. Y la razón es específica a lo que la fibrosis quística le hace al costo de energía del cuerpo.

It dropped because your weight dropped. And your weight dropped because you cut calories. That is what I want to explain to you, because in any other type of diabetes, cutting calories to lower blood sugar is a strategy that makes sense. In cystic fibrosis, it does not. And the reason is specific to what cystic fibrosis does to the body’s energy cost.

Why CF patients need twice the calories of a healthy adult

Rosa: — Cuando una persona sin fibrosis quística respira, el esfuerzo del diafragma y los músculos del pecho para mover el aire es relativamente pequeño — en una persona sana, respirar cuesta menos del cinco por ciento del gasto calórico total. En la fibrosis quística, los pulmones tienen obstrucción crónica, el moco es más resistente al movimiento del aire, la pared bronquial está engrosada, los bronquios están dilatados. Respirar con esos pulmones cuesta mucho más. La cantidad extra de trabajo que hacen sus músculos respiratorios todos los días, las 24 horas, es real y continua. Además, la infección bacteriana crónica de la Pseudomonas que tienen sus pulmones mantiene al sistema inmunológico activo — eso también consume energía.

When a person without cystic fibrosis breathes, the effort of the diaphragm and chest muscles to move air is relatively small — in a healthy person, breathing costs less than five percent of total caloric expenditure. In cystic fibrosis, the lungs have chronic obstruction, the mucus is more resistant to airflow, the bronchial wall is thickened, the bronchi are dilated. Breathing with those lungs costs much more. The extra amount of work your breathing muscles do every day, 24 hours a day, is real and continuous. Additionally, the chronic bacterial infection of the Pseudomonas in your lungs keeps the immune system active — that also consumes energy.

Carmen: — ¿Cuánto más?

How much more?

Rosa: — Las guías de nutrición en fibrosis quística recomiendan que los adultos con fibrosis quística consuman entre el 120 y el 150 por ciento de las calorías que consumiría una persona sana del mismo sexo, edad y talla. No porque la fibrosis quística haga que tengan más hambre — sino porque el cuerpo está quemando más. Una persona sana de su talla y edad podría mantener su peso con 2,000 calorías al día. Usted, con sus pulmones, probablemente necesita entre 2,400 y 3,000 para mantener el suyo. Cuando redujo a 1,400, creó un déficit que el cuerpo tuvo que compensar. Y el cuerpo siempre compensa lo mismo: usando reservas de grasa y de músculo.

The nutrition guidelines in cystic fibrosis recommend that adults with CF consume between 120 and 150 percent of the calories a healthy person of the same sex, age, and size would consume. Not because CF makes them more hungry — but because the body is burning more. A healthy person of your size and age could maintain their weight on 2,000 calories per day. You, with your lungs, probably need between 2,400 and 3,000 to maintain yours. When you reduced to 1,400, you created a deficit the body had to compensate for. And the body always compensates the same way: by using fat reserves and muscle.

Carmen: — Perdí nueve libras de grasa.

I lost nine pounds of fat.

Rosa: — Algo de grasa, sí. Y algo de músculo. Y en la fibrosis quística, el músculo que más importa cuando se pierde es el músculo respiratorio: el diafragma, los intercostales, los músculos accesorios del cuello y los hombros que usted usa cuando respira con esfuerzo. Esos músculos son los que generan la fuerza del tos que mueve el moco de sus pulmones. Cuando esos músculos se debilitan, la tos es menos eficaz, el moco se queda, las bacterias en el moco tienen más tiempo para multiplicarse, el riesgo de exacerbación sube.

Some fat, yes. And some muscle. And in cystic fibrosis, the muscle that matters most when it is lost is the respiratory muscle: the diaphragm, the intercostals, the accessory muscles of the neck and shoulders that you use when you breathe with effort. Those muscles are what generate the cough force that moves mucus out of your lungs. When those muscles weaken, the cough is less effective, the mucus stays, the bacteria in the mucus have more time to multiply, and the exacerbation risk rises.

Carmen: — ¿Y eso es lo que hice con la dieta?

And that is what I did with the diet?

Rosa: — Lo que vemos en sus números es consistente con eso. El 71% que tenía hace cuatro meses a 64% de hoy — siete puntos en cuatro meses, cuando estuvo estable durante dieciocho meses antes de eso. Y su frecuencia de síntomas respiratorios en las últimas cuatro semanas es la más alta que ha tenido en tres años. La correlación no es una coincidencia.

What we see in your numbers is consistent with that. The 71% you had four months ago to 64% today — seven points in four months, when you were stable for eighteen months before that. And your frequency of respiratory symptoms in the last four weeks is the highest you have had in three years. The correlation is not a coincidence.

How CF-related diabetes is actually treated

Carmen: — Pero los azúcares bajaron. Si vuelvo a comer como antes, los azúcares van a volver a subir.

But the blood sugars went down. If I go back to eating as before, the blood sugars will go back up.

Rosa: — Sí. Y eso es exactamente para lo que sirve la insulina. La diabetes relacionada con la fibrosis quística es diferente a la diabetes tipo 2 en algo fundamental: no hay resistencia a la insulina. El problema no es que las células de su cuerpo no respondan a la insulina — es que el páncreas no produce suficiente insulina suficientemente rápido cuando usted come. Lo que necesita no es menos glucosa para procesar — sino más insulina para procesar la glucosa que necesita comer para mantener los pulmones. La insulina de acción rápida antes de cada comida hace exactamente eso: provee la insulina que el páncreas no puede producir a tiempo para que usted pueda comer las calorías que sus pulmones necesitan.

Yes. And that is exactly what insulin is for. CF-related diabetes is different from type 2 diabetes in something fundamental: there is no insulin resistance. The problem is not that the cells of your body do not respond to insulin — it is that the pancreas does not produce enough insulin fast enough when you eat. What you need is not less glucose to process — but more insulin to process the glucose you need to eat to maintain your lungs. Rapid-acting insulin before each meal does exactly that: it provides the insulin the pancreas cannot produce in time so that you can eat the calories your lungs need.

Carmen: — ¿Tengo que inyectarme para poder comer?

Do I have to inject myself in order to eat?

Rosa: — La mayoría de las personas con diabetes relacionada con fibrosis quística usan insulina de acción rápida antes de las comidas — plumas de insulina, no jeringuillas; la dosis se calibra a lo que va a comer. Con el tiempo, aprende a ajustar la dosis según el tamaño de la comida, y deja de ser algo que piensa mucho. Lo que le puedo decir con certeza es que la alternativa que eligió — reducir las calorías lo suficiente para que el azúcar no suba — está funcionando para los azúcares y está costando siete puntos de FEV1 en cuatro meses. Eso, en fibrosis quística, es demasiado costoso.

Most people with CF-related diabetes use rapid-acting insulin before meals — insulin pens, not syringes; the dose is calibrated to what you are going to eat. Over time, you learn to adjust the dose according to meal size, and it stops being something you think about much. What I can tell you with certainty is that the alternative you chose — reducing calories enough that the blood sugar does not rise — is working for the blood sugars and is costing seven FEV1 points in four months. That, in cystic fibrosis, is too costly.

Carmen is quiet. She looks at the spirometry chart in her lap — the line that was flat for a year and a half and then began to fall.

Carmen: — Estaba haciendo lo correcto con la información que tenía.

I was doing the right thing with the information I had.

Rosa: — Exactamente. La estrategia que usó para cualquier otra persona con diabetes habría sido una estrategia razonable. La fibrosis quística es el contexto que cambia esa ecuación. No porque usted hiciera algo mal — sino porque el metabolismo de la fibrosis quística no funciona de la misma manera que el de alguien sin la enfermedad. Por eso el tratamiento también es diferente.

Exactly. The strategy you used would have been a reasonable strategy for any other person with diabetes. Cystic fibrosis is the context that changes that equation. Not because you did something wrong — but because the metabolism of cystic fibrosis does not work the same way as that of someone without the disease. That is why the treatment is also different.

Carmen: — ¿Cuánto tiempo antes de que la función pulmonar vuelva a subir?

How long before the lung function goes back up?

Rosa: — Si reiniciamos la insulina hoy, si empieza a comer las calorías que sus pulmones necesitan, y si en tres meses su peso volvió a donde estaba — esperamos ver la espirometría mejorar también. No podemos prometer cuánto, porque depende de cuánto del siete por ciento era reversible y cuánto era daño de exacerbaciones que tuviera sin saberlo. Pero el primer paso es estabilizar el peso y dejar de crear el déficit que está debilitando los músculos. Eso podemos empezar hoy.

If we restart the insulin today, if you start eating the calories your lungs need, and if in three months your weight is back to where it was — we expect to see the spirometry improve as well. We cannot promise how much, because it depends on how much of the seven points was reversible and how much was damage from exacerbations you were having without knowing it. But the first step is to stabilize weight and stop creating the deficit that is weakening the muscles. That we can start today.

Eight practical phrases for cystic fibrosis clinic nurses

“El medicamento corrige la proteína cada día que usted lo toma; el gen no cambia; la mejoría que siente es el medicamento funcionando y dura mientras el medicamento está presente.” (The medication corrects the protein every day you take it; the gene does not change; the improvement you feel is the medication working and it lasts as long as the medication is present.)
“Lo que su amigo vivió fue real — la mejora fue real, la sensación de estar bien fue real; lo que no era correcto era la conclusión: el medicamento es la razón por la que se siente bien, no la señal de que ya no lo necesita.” (What your friend experienced was real — the improvement was real, the feeling of being well was real; what was not correct was the conclusion: the medication is the reason you feel well, not the sign that you no longer need it.)
“Una exacerbación de fibrosis quística causa daño permanente en el tejido bronquial — los antibióticos intravenosos suprimen la infección para que el daño de esta exacerbación sea el menor posible, pero no pueden recuperar la función pulmonar que exacerbaciones anteriores ya destruyeron.” (A CF exacerbation causes permanent damage to the bronchial tissue — IV antibiotics suppress the infection so the damage from this exacerbation is as small as possible, but they cannot recover the lung function that previous exacerbations already destroyed.)
“Sin tratamiento, esta exacerbación va a durar más y causar más daño permanente que con tratamiento — el objetivo no es recuperar la función que ya se perdió, sino proteger la función que queda.” (Without treatment, this exacerbation will last longer and cause more permanent damage than with treatment — the goal is not to recover the function already lost, but to protect the function that remains.)
“La diabetes relacionada con la fibrosis quística no se trata reduciendo calorías — en la fibrosis quística el cuerpo quema entre el 120 y el 150 por ciento de las calorías normales porque respirar con pulmones obstruidos y combatir la infección crónica tienen un costo energético real y continuo.” (CF-related diabetes is not treated by reducing calories — in cystic fibrosis the body burns 120 to 150 percent of normal calories because breathing with obstructed lungs and fighting chronic infection have a real and continuous energy cost.)
“Cuando pierde peso en la fibrosis quística, los músculos del diafragma y de la tos se debilitan; una tos más débil mueve menos moco; el moco que no sale da a las bacterias más tiempo para multiplicarse y comenzar una exacerbación.” (When you lose weight in cystic fibrosis, the diaphragm and cough muscles weaken; a weaker cough moves less mucus; the mucus that does not leave gives bacteria more time to multiply and start an exacerbation.)
“La insulina de acción rápida antes de las comidas le permite comer las calorías que sus pulmones necesitan sin que el azúcar suba — el objetivo es tener suficiente insulina para procesar esas calorías, no reducir las calorías para no necesitar la insulina.” (Rapid-acting insulin before meals lets you eat the calories your lungs need without the blood sugar rising — the goal is to have enough insulin to process those calories, not to reduce the calories to avoid needing the insulin.)
“La terapia de depuración de vías aéreas dos veces al día mueve el moco antes de que las bacterias en él tengan tiempo de alcanzar una carga que dispare inflamación — es el hábito que más impacto tiene en cuántas exacerbaciones tiene al año.” (Airway clearance therapy twice a day moves mucus before the bacteria in it have time to reach a load that triggers inflammation — it is the habit that has the most impact on how many exacerbations you have per year.)

What each conversation required from the clinic nurse

Mónica did not dismiss what Adrián’s friend told him. She asked about the friend first, treating his source as a real source rather than a mistake to be corrected. That approach created the space in which Adrián could receive an explanation that was about mechanism rather than authority. The molecular explanation — the gene does not change, the medication does the correction work in real time, the improvement lasts as long as the medication lasts — was not presented as a contradiction of his friend’s experience. It was presented as the reason behind his friend’s experience, which made it something Adrián could pass on rather than something he had to choose between. The offer to share the explanation with the friend was not incidental. It was the moment Adrián became a vector for the correct information in a peer network that had already transmitted the incorrect version.

Elena began not with the plan for today but with the acknowledgment that Gloria’s observation was accurate: the lung function did not return after two courses of IV antibiotics. Starting there — with the truth the patient already knew — was what gave Elena credibility to explain why. A nurse who opened with “the antibiotics do work and you need them” would have been contradicting Gloria’s experience. Elena instead explained what the antibiotics were actually doing, which made the apparent failure of the previous courses coherent rather than contradictory. The phrase Gloria arrived at on her own — “the goal now is to slow the fall, not to recover” — is the most accurate summary of the clinical situation, and Gloria constructed it herself after being given the components. That construction is what made the decision to be admitted one Gloria made rather than one imposed on her.

Rosa acknowledged the success before she explained the cost. Carmen’s blood sugars were better. That was real. Denying it or minimizing it would have invalidated an accurate observation. Rosa confirmed it, then explained the CF-specific context that made the cost of that success higher than the benefit — the seven-point FEV1 drop, the weakened cough, the changed exacerbation trajectory. The metabolic distinction between CFRD and type 2 diabetes was necessary because Carmen’s strategy was drawn from type 2 diabetes literature. That literature was not wrong in its own context. In CF, the context is different, and explaining the specific mechanism — higher energy cost, muscle loss, reduced cough force, mucus retention — was what made the alternative (insulin rather than caloric restriction) comprehensible as a treatment rather than a capitulation.

The population this post is for

Cystic fibrosis was historically a disease of childhood and early adolescence in much of the world, but CFTR modulator therapy has transformed the life expectancy and disease trajectory of patients with eligible genotypes so dramatically that CF clinics are now managing a growing population of adults — including adults from Spanish-speaking backgrounds — whose experience of the disease is unlike anything that was possible a decade ago. The communication challenges that arise in this new era are specific to the era: patients who experienced a dramatic treatment transformation may not fully understand that the transformation is medication-dependent; patients whose disease has progressed despite treatment may not understand why treatment still matters; patients with emerging comorbidities like CFRD may apply information from other disease frameworks that does not transfer.

In California, Texas, Florida, Arizona, and Illinois — the states with the highest Spanish-as-primary-language populations and, not coincidentally, the largest CF clinic rosters — CF clinic nurses regularly encounter the gaps this post describes. The adolescent whose peer group now includes classmates whose CF symptoms are dramatically reduced and who cannot explain why, because the explanation was never given to them in language they owned. The middle-aged patient whose spirometry chart tells a story of progressive decline that no one has named clearly enough for her to understand what is at stake in each new exacerbation. The newly-diagnosed CFRD patient who reads the same diabetes information available to every diabetic patient without knowing that the CFRD-specific context makes that information actively harmful.

In each case, the clinic nurse’s clinical Spanish does not need to be perfect. It needs to be specific enough that the patient can describe the mechanism to someone who asks, recognize the failure mode before it recurs, and make an informed decision about treatment rather than a defensive one.

Practice these conversations at ClinicaLingo

ClinicaLingo offers AI-voiced clinical scenarios for working nurses, EMTs, PAs, and front-desk staff. The practice section covers the encounters you are most likely to have tomorrow — pulmonology clinic conversations, chronic disease adherence discussions, and diabetes management explanations in clinical Spanish. The free 50-phrase PDF includes the foundational vocabulary for chronic disease encounters. See also Spanish for pulmonology clinic nurses, Spanish for pediatric nurses, Spanish for infusion nurses, Spanish for endocrinology clinic nurses, Spanish for home health nurses, and the full clinical Spanish blog.

ClinicaLingo is a clinical Spanish learning tool for working clinicians. Content is written for educational purposes and does not constitute medical advice. Clinical protocols, dosing, and management decisions should follow your institution’s guidelines and the judgment of the treating physician.